Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Gynecologic 2CNS 2Sarcoma 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Solid Tumor 7Unspecified Adult Solid Tumor, Protocol Specific 3Mesothelioma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Sarcoma 1Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Lymphoma, B-Cell 1Hematopoietic and Lymphoid System Neoplasm 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 6Nivolumab 3tislelizumab 2budigalimab 2Ipilimumab 2Depsipeptides 2Decitabine 2venetoclax 1talazoparib 1spartalizumab 1sargramostim 1rovalpituzumab tesirine 1regorafenib 1poly ICLC 1iodixanol 1epacadostat 1entinostat 1durvalumab 1cemiplimab 1avelumab 1atezolizumab 1alvocidib 1Tomography, Optical Coherence 1Tissue Banks 1Tablets 1Radiosurgery 1Radiofrequency Ablation 1Paclitaxel 1Iohexol 1Interferon-gamma 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Fluorodeoxyglucose F18 × Other solid neoplasm × Clear all
NCT06503146 2026-05-19

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
320 enrolled
CNSEndocrineGastrointestinalGenitourinaryGynecologicOther solid neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Ovarian Neoplasms, Paraganglioma, Pheochromocytoma, Sarcoma, Stomach Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡